A Phase 3 interventional study of SYHX2008 and Sandostatin LAR® in Diagnosed With Acromegaly, Currently in the Active Stage of the Disease, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.
Among the 25 studies testing octreotide in Acromegaly, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 12 in phase 3, and was the 25th registered.
202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.
Browse Acromegaly studies →1 of the 25 studies testing octreotide in Acromegaly is open now.
Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 154 is above the median of 43 across 115 interventional studies indexed under Acromegaly.
Median enrollment 56 across the 25 interventional studies. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSPC ZhongQi Pharmaceutical Technology Co., Ltd., one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is the lead sponsor of 167 studies on the registry; 47 are open to participants now.
CSPC Pharmaceutical Group Limited has 3 studies filed under Acromegaly — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing octreotide in Acromegaly, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
he purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in in patients with acromegaly.
This study is a randomized, parallel, open-label, multicenter, positive-controlled, superiority-designed Phase III clinical study evaluating the efficacy and safety of octreotide long-acting injection in patients with acromegaly. The purpose of this study is to evaluate the efficacy and safety of SYHX2008 injection in treating acromegaly. Patients will be randomized to SYHX2008 cohort or Octreotide Microspheres(Sandostatin LAR®) cohort. A total of 154 participants are expected to be enrolled. The study will consist of a maximum 4-week screening/Baseline period, followed by 28-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SYHX2008
Drug: SYHX2008
Sandostatin LAR®
Drug: Sandostatin LAR®
The patients will accept SYHX2008 injection by subcutaneous administration.A treatment period of 28 weeks.
The patients will accept Sandostatin LAR@ by intra-muscular administration.A treatment period of 28 weeks.
The proportion of patients with an IGF-1 index ≤ 1.0
insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range
Time frame: Week 28
The proportion of patients with fasting GH less than 2.5 ng/mL and IGF-1 index less than or equal to 1.0
Time frame: weeks 4、8、12、16、20、24、28
The proportion of patients with GH less than 1.0 ng/mL and IGF-1 index less than or equal to 1.0
Time frame: weeks 4、8、12、16、20、24、28
The proportion of patients with fasting GH < 1.0 ng/mL
Time frame: Weeks 4、8、12、16、20、24、28
The proportion of patients with fasting GH<2.5 ng/mL
Time frame: Weeks 4、8、12、16、20、24、28
The proportion of patients with an IGF-1 index ≤ 1.0
insulin-like growth factor-1 within the normal range after adjustment for age and gender, where IGF-1 index = IGF-1 value/ULN, and ULN is the upper limit of the normal reference range
Time frame: Weeks 4、8、12、16、20、24
The rate of change in the volume of the pituitary tumor from the baseline
Time frame: Weeks 28
The change in the total PASQ score from the baseline
Evaluation of effect on was assessed using Patient Assessed Acromegaly Symptom Question ( PASQ ), an acromegaly-specific quality of life instrument.
Time frame: Weeks 12、28
The change in the total AcroQoL score from the baseline
Evaluation of effect was assessed using Acromegaly Quality of Life Questionnaire(AcroQoL), an acromegaly-specific quality of life instrument.
Time frame: Weeks 12、28
The proportion of patients with fasting GH decreased by ≥50% compared to the baseline
Time frame: Weeks 4、8、12、16、20、24、28
The proportion of patients whose IGF-1 index decreased by ≥50% compared with the baseline
Time frame: Weeks 4、8、12、16、20、24、28
Percentage changes in fasting GH from baseline
Time frame: Weeks 4、8、12、16、20、24、28
Percentage changes in IGF-1 from baseline
Time frame: Weeks 4、8、12、16、20、24、28
Incidence of adverse events (AE)
Proportion of subjects with adverse events (AEs) within Weeks 28
Time frame: From the signing of informed consent up to 28 Weeks after the first dose
The concentration of octreotide
The concentration of octreotide in the plasma of patients with acromegaly after administration of SYHX2008 injection and Sandostatin LAR®
Time frame: From the signing of informed consent up to 28 Weeks afterthe first dose
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Jul 2029, 38 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: SYHX2008 · Octreotide
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. →